August 20, 2019
By Reuters Health
(Reuters) - Teva Pharmaceutical Industries Ltd on Tuesday made its generic version of Mylan's EpiPen for young children available in most retail pharmacies at $300 for a 2-pack.
Teva, the world's largest generic drugmaker, is already selling the product for adults, after getting U.S. approval for its copy of EpiPen last August, following several years of delay.
Mylan also produces a generic version of its own life-saving EpiPen allergy treatment, which like Teva's product is priced at about $300.
There has been a shortage of EpiPens in the United States, Europe and Canada, mainly due to a series of manufacturing delays at Pfizer Inc's Meridian Medical unit that produces all EpiPens sold globally at a single plant near St. Louis.(c) Copyright Thomson Reuters 2019. Click For Restrictions - https://agency.reuters.com/en/copyright.html